This was the stock's fifth consecutive day of gains.

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: Regeneron Pharmaceuticals ( REGN 0.40%) and Moderna ( MRNA -0.79%).

Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.43% to $554.18 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.81% to 5, ...

BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday ...

Cantor Fitzgerald upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Intuitive ...